Galapagos NV American Depositary Shares (GLPG)

FairStock Score: 88/100 — HIGH CONVICTION

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

As a value investor, I want a business I can understand and a price that protects me from error. Galapagos is a development-stage biotech, not a predictable compounding machine. In fiscal Q1 2026, revenue was only $6.5 million while net income was $14.5 million—a rare quarter where income exceeded sales. That tells me the earnings are not yet driven by a durable commercial engine. Trailing free cash flow was negative $310.3 million, a -16.0% FCF yield on the $1.9 billion market cap, so the company is consuming capital. Still, the balance sheet shows no debt (D/E 0.00), an Altman Z-Score of 10.86, and FairStock ROE of 10.42% and ROCE of 8.87%. At the 2026-07-02 close of $30.39, FairStock calculates a P/E of 5.31, P/B of 10.48, EV/EBITDA of 4.72, and PEG of 0.01. The Graham Number is $79.71, suggesting a 61.87% margin of safety, which is the main attraction. But Graham would also ask: is this asset value real and durable? The pipeline—GLPG3667 in Phase 2, GLPG5101 and GLPG5301 in earlier CAR-T trials—offers optionality but no proven moat. The Piotroski F-Score of 4/9 and negative FCF argue for caution. The FairStock Score is 88/100, and the Lynch category is 'none' because only zero years of filed results are available, so this does not meet a Lynch rule. My conclusion: statistically cheap, financially under-earning, and dependent on clinical success. Price alone is not enough; I need evidence the cash burn leads to approved medicines.

In plain English: Galapagos is a small biotech developing medicines for cancer and immune diseases. It has almost no debt and earned a profit in its latest quarter, but it burned cash over the past year and its regular sales are tiny. Based on the numbers provided, the shares look cheap against reported earnings and one value measure, but that cheapness carries high risk because its treatments are still in testing.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-07-02 close · note generated 2026-10-15 · model deepseek-flash

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer